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ABSTRACT
Two diphenylantimony(lll) derivatives of dithiophosphorus ligands, i.e. Ph2SbS2PPh2 and
Ph2SbS2P(OPr-i)2, which were previously found to exhibit antitumor properties, have been now
investigated for potential mutagenic effects in healthy and Ehrlich ascites tumor-bearing mice. Two
shod-term tests, i.e. the micronucleus test and the cytogenetic analysis, were used as end-points
for mutagenicity. The results are consistent with a mutagenic potential for both organoantimony(lll)
compounds tested, the effect being higher for the phosphomdithioato derivative.
INTRODUCTION
Cancer remains one of the major causes of death in humans and many efforts are in
progress in the fight against this disease, including new treatments and new antitumor agents, i.e.
metal compounds. 1"3 The use of chemotherapy in cancer treatment has always been hampered by
the possible side effects of the drugs applied, irrespective of their antitumor effects.
The platinum Compounds and especially Cisplatin are active antitumor drugs, but revealed
systemic toxicity4,5 and even mutagenicity.6-8 The screening of anticancer agents includes the
testing of their cytotoxic and genotoxic potential by in vitro and in vivo assays,9-11 arranged in a
logic succession, from in vitro short-term investigations to in vivo long-term experiments on
successive animal generations12,13 and clinical trials on humans.9,12,14 Usually the first steps of
the screening include the bacterial assays (Ames test,9,14 SOS Chromotest15) and the cytogenetic
analysis (the micronucleus test13,16,17 and chromosome aberrations13,18).
During the last fiftheen years much attention was focussed on the antitumor properties of
new organometallic compounds. 1,2 A large number of organotin derivatives, some of them being
first investigated for their biocidal properties towards bacteria, fungi and mammals,19 were found to
exhibit antitumor activity. 1"3,20,21 Recently, two diphenylantimony(lll) derivatives of
dithiophosphorus ligands were mentioned as the first organoantimony compounds exhibiting
antitumor properties.2225 The genotoxic properties of organoantimony compounds are practically
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not investigated, and, so far, only one inorganic antimony compound was reported to exhibit
mutagenic potential against human lymphocytes.26
Our investigations, reported here, are focused on the mutagenic properties of the two
diphenylantimony(lll) derivatives previously tested fot their antitumor effects on animal tumor
systems.2225 The micronucleus test and the cytogenetic analysis were used as sensible end-
points for testing their mutagenicity. These assays were applied comparatively on organoantimony-
treated, healthy or Ehrlich ascites tumor (EAT) bearing mice.
MATERIALS AND METHODS
Animals. Six-months old, AKR male mice (25+2 g) (provided by the Oncology Institute of
Cluj-Napoca) were used in all experiments. The Ehrlich ascites tumor (Lettre variant) was maintained
weekly by intraperitoneal injections of 2x106 tumor cells per mouse.
Compounds. The two organoantimony(lll) derivatives, I.e. (diphenylphosphinodithioato)di-
phenylantimony(lll), Ph2SbS2PPh2 (compound 1), and (di-isopropylphosphomdithioato)diphenyl-
antimony(Ill), Ph2SbS2P(OPr-i)2 (compound 2), were prepared and purified as described
earlier.27,28 Both compounds were used at two concentrations (total dose of 10 and 20 mg/kg of
body weight) in all the experiments.
In vivo experiments. Ten groups, each of ten animals (five groups of healthy mice and five
groups of EAT-bearing mice) were used for the screening of the title compounds. The treatment
was started 24 hours after the tumor transplant.
Experiment I: Four groups of healthy animals were used for the administration of each
organoantimony compound, at the two concentration levels. One group of healthy, untreated mice
was considered as negative control (NC).
Experiment I1: Four groups of EAT-bearing mice were treated with the organoantimony
derivatives, at the same concentration doses as above. One group of untreated, EAT-bearing mice
was used as positive control (C).
The total doses of 10 or 20 mg/kg of the tested compounds were applied on days 1,3 and
5 after tumor transplantation (day 0). For the healthy mice groups, the treatments were applied in
the same days. All the animals were sacrified at 24 hours after the last treatment. Two hours before
the sacrifice each mouse was injected with 1.5 ml colchicine 0.02%. Their bone marrow cells were
collected from both femora by flushing with 2.5 ml MEM containing 20% fetal calf serum. The cell
suspension from ,,each experimental lot was partitioned in two aliquots, in order to apply the
micronucleus test and the chromosomal analysis.
Micronucleu$ test. The cell suspension was centrifugated at 1500 rpm and the pellet was
spread directly on slides, without fixation. The air-dried preparations were stained by the May-
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GrQnwald Giemsa method.29 Two slides/mouse were prepared and examined microscopically. The
polychromatic erythrocytes (PE) and micronuclei-containing PE (PEm), respectively, were counted
from ca. 1000 erythrocytes. The results were expressed as the average number of PE (%) from total
erythrocytes, and of micronucleated PEm (%) from one hundred PE. The statistical evaluation of
the experimental vs. control data was calculated using the Student "t" test and the significance of
the differences was set at 0.01 level.
Chromosomal analysis. The bone marrow cell suspension was centrifugated at 1500 rpm
and the pellet was resuspended for 30 min. in a 0.7% natrium citrate hypotonic solution. The
standard cytogenetic method was applied and finally the lymphoid cells were smeared on slides, air-
dried and counted. For evaluation of the mitotic index (MI), 1000 cells from each slide were scored
and the % of metaphases was recorded. Ten metaphases from each slide were examined,
photographed and analysed in order to identify the number and the type of the chromosomal
aberrations (chromatid or chromosome breaks and exchanges).
RESULTS AND DISCUSSION
The mean pement values of polychromatic erythrocytes (%PE) from total erythrocytes and
of micronucleated polychromatic (%PEm) from total PE, respectively, are presented in Table 1.
Table 1. Mean values (x), standard errors (+s) and statistical significance (S) of differences
against controls (NC and C) for the parameters determined from the micronucleus
test, after treatments with diphenylantimony(lll) compounds (for the significance of
the symbols, see Materials and Methods).
Treatment %PE %PEru
(Exp-Cpd-Dose)a x ,-h3 Sb x -+S Sb
NC 42.5 1.5 0.30 0.03
I- 1 10 40.0 1.1 NS 1.45 0.40 *
I- 2- 10 38.5 1.0 NS 2.50 0.72 **
1 20 38.0 0.9 * 1.80 0.50 **
2 20 36.5 0.8 *** 2.75 0.80 **
C 48.6 2.8 0.55 0.05
II- 1 10 48.0 1.8 NS 1.80 0.55 NS
II- 2- 10 45.0 1.3 NS 2.50 0.80 NS
II 1 20 40.0 1.1 * 2.80 0.95 *
II 2- 20 36.0 0.8 *** 3.30 1.00 *
a Experiment (I or II) Compound (1 or 2) Dose (10 or 20 mg/kg); b,. p < 0.01, ** p < 0.005,
*** p < 0.001.
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A general decrease of %PE and an increase of %PEru compared to controls (NC and C)
were observed for all the organoantimony-treated mice. These effects were dose-dependent and
more pronounced for compound 2 than for compound 1. Almost the same intensity of these
effects was observed in healthy or Ehrlich tumor bearing mice.
Micronuclei originate from chromosomal material that has lagged in anaphase and was not
included in the main nucleus of daughter cells. They are identified as dark-blue-staining bodies in
the cytoplasm of PE which are coloured blue-pink, differently from mature normochromatic
erythrocytes. 16 Figure 1 shows two different micronuclei identified from the Experiments
(A, 2 20) and II (B, II 2 20), in which a dose of 20 mg/kg of compound 2 was used.
Figure 1. Micronuclei identified in polychromatic erytrocytes from healthy mice (A) and EAT-
bearing mice (B) treated with 20 mg/kg of compound 2.
The statistical evaluation of our results (the differences against controls Table 1) revealed
significant inhibition of PE at higher doses and significant stimulation of micronuclei formation in
bone marrow cells from healthy mice, especially for compound 2. In spite of these differences, it is
difficult to design this compound as a strong mutagen. So far, the interpretation of the
micronucleus test results remains difficult, the limit between a positive and a negative result being
not yet established. 16 Generally, when the experimental values exceed ten times the control
values, the tested compound is considered as a mutagen, but even this Ilmit is not always
accepted.16,17
Concomitently, the metaphase analysis was performed for the same experiments. Table 2
presents the mitotic index (MI) of bone marrow lymphocytes and the frequency of chromatid and
chromosomal aberrations (breaks and exchanges). A general decrease in the mitotic index was
observed in both experiments, the effect being dose-dependent and more pronounced when
treatment with compound 2 was used. The most frequent aberrations of bone marrow cells were at
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chromatid level. The percentage of total aberrations was higher for compound 2, especially in EAT-
bearing mice. Figure 2 reveals two metaphases containing chromatidic breaks or exchanges, due to
the administration of 20 mg/kg compound 2 to EAT-bearing mice.
Table 2. Mean values of the mitotic index (MI) and frequencies of chromosomal aberrations
in bone marrow lymphocytes after the in vivo treatment with diphenylantimony(lll)
compounds (for the significance of the symbols, see Materials and Methods).
Treatment MI Chromatid aberrat,a Chromosome aberrat,a Total aberrat.
Exp-Cpd-Dose)b breaks exchanges breaks exchanges (%)
NC 0.08 2 0 0 0 2
1 10 0.05 1 0 1 0 2
I- 2- 10 0.04 3 1 0 0 4
I- 1-20 0.05 2 1 1 0 4
2- 20 0.02 4 2 2 0 8
C 0.15 5 1 1 0 7
II- 1-10 0.12 4 2 1 0 7
11-2-10 0.10 5 2 2 1 10
II- 1-20 0.10 5 1 2 1 9
II 1 20 0.09 8 3 2 1 1 4
aMean values per 100 cells scored/slide; b The same abreviations as for Table 1.
II __.IILI
Figure 2, Metaphase chromosomes with chromatidic a berrations (breaks and exchanges
see the arrows) obtained from lymphocytes of EAT-bearing mice, after treatment
with 20 mg/kg of compound 2.
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Both methods, i.e. the micronucleus test and the metaphase analysis, are considered as
equally sensitive for evaluating the mutagenicity. Most regulatory guidelines leave the choice to the
investigator as to which of these tests to use for best-set screening.16 We are considering that a
simultaneous use of both methods might better reflect the real effect of the tested compounds.
Our results suggest that both compounds could have a mutagenic potential at the higher
dose used (i.e. 20 mg/kg). This effect is more pronounced for (di-isopropylphosphoro-
dithioato)diphenylantimony(lll) (compound 2), and is in good agreement with our previous
observations concerning its cytotoxicity23,24 and its genotoxicity evaluated using SOS
Chromotest,30 a well known bacterial test15 for the identification of the mutagens.
CONCLUSIONS
Our previous studies concerning the antitumor activity of the same two diphenyl-
antimony(Ill) compounds revealed a stronger tumor growth inhibition produced by the phosphom-
dithioato derivative than the phosphinodithioato analogue. This activity was demonstrated in vitro
and in vivo by an inhibition of tumor cell viability and proliferation, and an unbalance of ATP-
producing and -consuming processes during the cell-cycle.
The present experiments have used as marker the bone marrow cells from healthy and
EAT-bearing mice, and applied two short-term in vivo tests, i.e. the micronucleus test and the
cytogenetic analysis, as end-points for mutagenicity. The results obtained from both tests
compared well and revealed a mutagenic potential for both compounds used. The intensity of this
effect was higher for the (di-isopropylphosphorodithioato)diphenylantimony(lll). Another
genotoxicity test, i.e. SOS Chromotest, confirmed the present results. It remains to be investigated
how the results of these short-term tests could be correlated with long-term cancer studies. Further
studies concerning this topic are in progress.
REFERENCES
1. I. Haiduc and C. Silvestru, Organometallics in Cancer Chemotherapy, CRC Press, Boca
Raton, Florida, Vol.I. Main Group Metal Compounds, 1989; Vol.ll. Transition Metal
Compounds, 1990.
2. M. Gielen (Ed.), Metal-Based Anti-Turnout Drugs, Freund Publ. House Ltd., London; Vol.1,
1988; Vol.2, 1992.
3. B.K. Keppler (Ed.), Metal Complexes in Cancer Chemotherapy, VCH, Weinheim
(Germany), 1993.
4. A.M.J. Fichtinger-Schepman, A.T. Van Oostemn, P.H.M. Lohman and F. Berends,
Mutation Res., 1987,190, 159.
296C. Socaciu, L Paaca, C. Silveatru, A. bars andL Hatduc MetalBasedDrugs
D. Wierda and T.L. Pazdernic, Eur. J. Cancer., 1979, 15, 1013.
L.A. Loeb and R.A. Zakour, in Nucleic Acid-Metal /on Interactions, (T.G. Spire, Ed.),
J.Wiley & Sons, New York, 1978, p. 117.
T.C. Hsu, L.M. Cherry and S. Pathak, Mutation Res., 1982, 93, 185.
E. Bocian, M. Laverick and A.H.W. Nias, Br. J. Cancer, 1983, 47, 503.
R.K.Y. Zee-Cheng and C.C. Cheng, Meth. Find. C/in. Pharmacol., 1988, 10, 67.
J.J. Roberts and M.F. Pera, Jr., in Platinum, Goldand Other Metal Chemotherapeutic
Agents: Chemistryand Biochemistry, (S.J. Lippard, Ed.), ACS Symposium Series, 1983,
209, 15.
F.W. Sunderman, Jr., in Environmental Carcinogenesis, (P. Emmelot and E. Kriek, Eds.),
Elsevier, Amsterdam, 1979, p. 3.
A.V. Carrano and A.T. Natarajan, Mutation Res., 1988, 204, 379.
M. Ishidate, Jr., M.C. Harnois and T. Sofuni, Mutation Res., 1988, 195, 151.
J. Ashby, Mutation Res., 1988, 204, 543.
P. Quillardet and M. Hofnung, Mutation Res., 1993, 297, 235.
I.D. Adler, in Mutagenicity Testing- A PracticalApproach, (S. Venitt and J.M. Parry, Eds.),
RL Press, Oxford, 1984, p. 275.
J.A. Heddle and A.V. Carrano, Mutation lies., 1977, 44, 63.
A.K. Sinha, V.A. Linscombe and B.B. Gollapudi, Mutation Res., 1989, 226, 65.
C. Socaciu, PhD Thesis, Babes-Bolyai University, Cluj-Napoca, Romania, 1986.
A.J. Crowe, Drugs of the Future, 1987, 12, 255.
M. Gielen (Ed.), Tin-BasedAntitumor Drugs, NATO AS/Series: Cell Biology, Springer
Verlag, Berlin, 1990, Vol. 37.
C. Silvestru, C. Socaciu, A. Bara and I. Haiduc, Anticancer Res., 1990, 10, 803.
A. Bara, C. Socaciu, C. Silvestru and I. Haiduc, Anticancer Res., 1991, 11, 1991.
C. Socaciu, A. Bara, C. Silvestru and I. Haiduc, InVivo, 1991,5, 425.
B.K. Keppler, C. Silvestru and I. Haiduc, Metal-Based Drugs, 1994, 1 (in press).
G.R. Paton and A.C. Allison, Mutation Res., 1972, 16, 332.
C. Silvestru, L. Silaghi-Dumitrescu, I. Haiduc, M.J. Begley, M. Nunn and D.B. Sowerby,
J. Chem. Soc., Dalton Trans., 1986, 1031.
C. Silvestru, M. Curtui, I. Haiduc, M.J. Begley and D.B. Sowerby, J. Organomet. Chem.,
1992, 426, 49.
N. Schmid, Agents and Actions, 1973, 3, 77.
C. Socaciu, I. Pasca and O. Bobis, unpublished results.
Received: October 27, 1993 Accepted: January 10, 1994
297